Home > Haematology > ASH 2020 > Chronic Leukaemia > Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs

Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs

Presented By
Dr Hagop Kantarjian, MD Anderson Cancer Center, Texas, USA
Conference
ASH 2020
Trial
OPTIC, PACE
In a combined analysis of 2 pivotal trials, comprising the largest number of patients with chronic-phase chronic myeloid leukaemia (CP-CML) who had failed second-generation tyrosine kinase inhibitors (TKIs), ponatinib demonstrated high response rates and robust survival outcomes [1]. Resistant patients with CP-CML who have failed ≥1 second-generation TKI have poor outcomes when they switch to another second-generation TKI. There is limited clinical evidence to support that switching to third-generation TKI therapy improves long-term clinical outcomes for these patients. The PACE and OPTIC trials evaluated outcomes with ponatinib in difficult-to-treat CP-CML patients [2,3]. In the PACE trial, patients with resistant and intolerant CP-CML who failed prior second-generation TKI therapy demonstrated deep and long-lasting responses to ponatinib [2]. A posthoc modelling analysis of the data from PACE suggested a relationship between dose...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on